Quotient Ltd (NASDAQ:QTNT) shares are trading higher Wednesday after the company issued guidance above analyst estimates.
Quotient announced that it has rescheduled its financial results to June 24. The company provided a preview of its results in accordance with the rescheduling.
Quotient said it expects product sales from its reagent business to be $9.8 million in the fourth quarter and $38.5 million for the full year. Average analyst estimates expect the company to report revenue of $8.17 million in the fourth quarter, according to data from Benzinga Pro.
Quotient is a commercial-stage diagnostics company that is involved in the development, manufacturing and commercialization of conventional reagent products used for blood grouping within the global transfusion diagnostics market.
See Also: Why Athira Pharma Stock Is Plunging
QTNT Price Action: Quotient has traded between $4.40 and 27 cents over a 52-week period.
The stock was up 31.1% at 49 cents at time of publication.
Photo: fernando zhiminaicela from Pixabay.
